146 related articles for article (PubMed ID: 24672123)
41. Darbepoetin alfa administered monthly maintains haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis: a multicentre, open-label, Australian study.
Disney A; Jersey PD; Kirkland G; Mantha M; Charlesworth JA; Gallagher M; Harris D; Gock H; Mangos GJ; Macmillan J; Liu W; Viswalingam A
Nephrology (Carlton); 2007 Feb; 12(1):95-101. PubMed ID: 17295668
[TBL] [Abstract][Full Text] [Related]
42. Darbepoetin alfa for the treatment of anemia in children undergoing peritoneal dialysis: a multicenter prospective study in Japan.
Hattori M; Matsunaga A; Akioka Y; Fujinaga S; Nagai T; Uemura O; Nakakura H; Ashida A; Kamei K; Ito S; Yamada T; Goto Y; Ohta T; Hisano M; Komatsu Y; Itami N
Clin Exp Nephrol; 2013 Aug; 17(4):582-8. PubMed ID: 23089940
[TBL] [Abstract][Full Text] [Related]
43. Extended dosing of darbepoetin alfa in peritoneal dialysis patients.
Feriani M; De Meester JM; McMahon LP; Rottembourg JB; Bridges I; Farouk M; Pronai W
BMC Nephrol; 2011 Mar; 12():13. PubMed ID: 21435267
[TBL] [Abstract][Full Text] [Related]
44. Initiation of darbepoetin for management of anemia in non-dialysis-dependent patients with chronic kidney disease.
Al Raisi F; Al Salmi I; Kamble P; Al Shehri M; Shaheen FA
Saudi J Kidney Dis Transpl; 2016; 27(6):1182-1187. PubMed ID: 27900963
[TBL] [Abstract][Full Text] [Related]
45. A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia.
Pergola PE; Gartenberg G; Fu M; Wolfson M; Rao S; Bowers P
Clin J Am Soc Nephrol; 2009 Nov; 4(11):1731-40. PubMed ID: 19808215
[TBL] [Abstract][Full Text] [Related]
46. [Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa].
Molina M; García Hernández MA; Navarro MJ; Pérez Silva F; Cacho M; De Gracia MC
Nefrologia; 2004; 24(1):54-9. PubMed ID: 15083958
[TBL] [Abstract][Full Text] [Related]
47. Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease.
Suranyi MG; Lindberg JS; Navarro J; Elias C; Brenner RM; Walker R
Am J Nephrol; 2003; 23(2):106-11. PubMed ID: 12481149
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study.
Nangaku M; Kondo K; Ueta K; Kokado Y; Kaneko G; Matsuda H; Kawaguchi Y; Komatsu Y
Nephrol Dial Transplant; 2021 Aug; 36(9):1731-1741. PubMed ID: 33650630
[TBL] [Abstract][Full Text] [Related]
49. Efficient monthly subcutaneous administration of darbepoetin in stable CAPD patients.
Theodoridis M; Passadakis P; Kriki P; Panagoutsos S; Yannatos E; Kantartzi K; Sivridis D; Vargemezis V
Perit Dial Int; 2005; 25(6):564-9. PubMed ID: 16411523
[TBL] [Abstract][Full Text] [Related]
50. Randomized study of darbepoetin alfa and recombinant human erythropoietin for treatment of renal anemia in chronic renal failure patients receiving peritoneal dialysis.
Li WY; Chu TS; Huang JW; Wu MS; Wu KD
J Formos Med Assoc; 2008 Nov; 107(11):843-50. PubMed ID: 18971153
[TBL] [Abstract][Full Text] [Related]
51. Complete switch to darbepoetin in a hemodialysis unit.
Shalansky K; Jastrzebski J
Clin Nephrol; 2005 Jul; 64(1):55-63. PubMed ID: 16047646
[TBL] [Abstract][Full Text] [Related]
52. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
53. Oxidative stress, inflammation and nutritional status during darbepoetin alpha treatment in peritoneal dialysis patients.
Malgorzewicz S; Lichodziejewska-Niemierko M; Lizakowski S; Liberek T; Lysiak-Szydlowska W; Rutkowski B
Clin Nephrol; 2010 Mar; 73(3):210-5. PubMed ID: 20178720
[TBL] [Abstract][Full Text] [Related]
54. Darbepoetin alfa administration to achieve and maintain target hemoglobin levels for 1 year in patients with chronic kidney disease.
Hertel JE; Locay HR; Scarlata DS; Prathikanti R; Audhya PK
Mayo Clin Proc; 2006 Sep; 81(9):1188-94. PubMed ID: 16970215
[TBL] [Abstract][Full Text] [Related]
55. Randomized, double-blind, placebo-controlled study to evaluate the effect of two dosing regimens of darbepoetin alfa in patients with heart failure and anaemia.
van Veldhuisen DJ; Dickstein K; Cohen-Solal A; Lok DJ; Wasserman SM; Baker N; Rosser D; Cleland JG; Ponikowski P
Eur Heart J; 2007 Sep; 28(18):2208-16. PubMed ID: 17681958
[TBL] [Abstract][Full Text] [Related]
56. Darbepoetin alfa: a novel erythropoiesis-stimulating protein.
Cases A
Drugs Today (Barc); 2003 Jul; 39(7):477-95. PubMed ID: 12973399
[TBL] [Abstract][Full Text] [Related]
57. Efficacy and safety of darbepoetin alfa for anemia in children with chronic kidney disease: a multicenter prospective study in Japan.
Hattori M; Uemura O; Hataya H; Ito S; Hisano M; Ohta T; Fujinaga S; Kise T; Gotoh Y; Matsunaga A; Ito N; Akizawa T;
Clin Exp Nephrol; 2014 Aug; 18(4):634-41. PubMed ID: 24013765
[TBL] [Abstract][Full Text] [Related]
58. C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis.
Bastos K; Lucarelli LA; De Francesco-Daher E; Filho RP; Henríquez C; Espinoza B; Villanueva I; Schwedt E; Schiavelli R; Correa-Rotter R
Int Urol Nephrol; 2013 Oct; 45(5):1355-64. PubMed ID: 22990412
[TBL] [Abstract][Full Text] [Related]
59. Darbepoetin versus epoetin alfa for the correction of anemia in cancer patients receiving radiotherapy or chemoradiotherapy treatment.
Ots PM; Carrizosa CL; Pérez AR; de Dios Saez Garrido J; Pérez JM
Clin Med Oncol; 2008; 2():393-9. PubMed ID: 21892305
[TBL] [Abstract][Full Text] [Related]
60. Once-weekly epoetin alfa dosing is as effective as three times-weekly dosing in increasing hemoglobin levels and is associated with improved quality of life in anemic HIV-infected patients.
Grossman HA; Goon B; Bowers P; Leitz G;
J Acquir Immune Defic Syndr; 2003 Dec; 34(4):368-78. PubMed ID: 14615654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
